MarketAxess Holdings (MKTX) Tops Q2 EPS by 6c; Sees Higher FY13 CapExh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MKTX Hot Sheet
Price: $164.67 +0.01%
Financial Fact:
Total revenues: 90.27M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total revenues: 90.27M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
MarketAxess Holdings (NASDAQ: MKTX) reported Q2 EPS of $0.51, $0.06 better than the analyst estimate of $0.45. Revenue for the quarter came in at $65.6 million versus the consensus estimate of $64.4 million.
The Company is updating its full year 2013 capital spending guidance and now expects total capital expenditures for 2013 will be in the range of $21.0 million to $24.0 million, up from the latest guidance of $15.0 million to $18.0 million.
For earnings history and earnings-related data on MarketAxess Holdings (MKTX) click here.
The Company is updating its full year 2013 capital spending guidance and now expects total capital expenditures for 2013 will be in the range of $21.0 million to $24.0 million, up from the latest guidance of $15.0 million to $18.0 million.
For earnings history and earnings-related data on MarketAxess Holdings (MKTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Accenture shares fall on insider sales and analyst downgrade
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
